HPBCD for the treatment of irreversible white matter injury
White matter repair relies on microglial clearance of cholesterol-rich myelin debris. Microglia have been reported to predominantly depend on de
Tag: stroke
Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and
HPβCD’s Promise in Treating Ischemic Stroke
Ischemic stroke is a leading cause of mortality and long-term disability worldwide, with limited pharmacological interventions available. 2-hydroxypropyl-β-cyclodextrin (HPβCD), a
HPBCD accesses acute and subacute infarcts in a mouse model of ischemic stroke
Ischemic stroke is a leading cause of mortality and long-term disability worldwide, with limited pharmacological interventions available. Researchers in Arizona
Oral Xenon/alpha-Cyclodextrin Provides Neuroprotection for Ischemic Stroke
Ischemic stroke is one of the main causes of long-term morbidity/mortality and early treatment of stroke is key issue. Xenon
Repeated administration of 2-hydroxypropyl-β-cyclodextrin (HPβCD) attenuates the chronic inflammatory response to experimental stroke
Globally, more than 67 million people are living with the effects of ischemic stroke. Importantly, many stroke survivors develop a